Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Syncona

    - PMLiVE

    Major prostate cancer screening trial launched in UK

    The £42m Transform trial will recruit men aged 50-74, with a lower age limit of 45 for some men

    - PMLiVE

    Europe Celebrates the Heart of Healthcare Decision-Making as Laboratory Medicine Professionals Take Centre Stage

    Today, the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) proudly marks European Laboratory Day, celebrating the professionals at the heart of healthcare decision making. Across Europe, laboratories will...

    EatMoreFruit

    - PMLiVE

    Pfizer/Astellas share positive overall survival results for Xtandi in prostate cancer

    Around 55,100 cases of prostate cancer are diagnosed in the UK every year

    - PMLiVE

    Roche to boost US footprint with $50bn investment over next five years

    The commitment is aimed at bolstering the company’s pharmaceutical and diagnostics divisions

    - PMLiVE

    Novartis’ Pluvicto granted FDA approval for expanded prostate cancer use

    The authorisation approximately triples the number of patients eligible to receive the therapy

    - PMLiVE

    ICR researchers uncover genes responsible for tumour progression in prostate cancer

    The findings could pave the way for new treatment approaches that improve patient outcomes

    - PMLiVE

    Prostate cancer blood test with ‘unprecedented accuracy’ cuts biopsies by 50%

    There is currently no national screening programme for prostate cancer in the UK

    - PMLiVE

    ICR study reveals how PARP inhibitor resistance develops in prostate cancer patients

    The research could pave the way for the development of new drugs that prevent drug resistance

    - PMLiVE

    AstraZeneca announces positive results for Truqap in phase 3 prostate cancer study

    More than 52,000 cases of prostate cancer are diagnosed in the UK every year

    - PMLiVE

    Pfizer shares positive phase 3 results for Talzenna combination in prostate cancer

    Up to 20% of patients will develop metastatic castration-resistant disease within five to seven years of diagnosis

    - PMLiVE

    J&J’s Erleada shows overall survival benefit in head-to-head prostate cancer study

    Approximately 300,000 new cases of the disease are diagnosed in the US every year

    - PMLiVE

    ICR researchers identify new drug target for advanced prostate cancer patients

    The team estimates that around 10% of patients have high levels of the BCL2 protein

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links